华北制药：预计2025年半年度净利润同比增加72%左右

Group 1 - The company, North China Pharmaceutical (600812), expects to achieve a net profit attributable to shareholders of approximately 124 million yuan for the first half of 2025, representing an increase of about 51.52 million yuan compared to the same period last year, which is a year-on-year increase of approximately 72% [1] - The company anticipates that the net profit attributable to shareholders after deducting non-recurring gains and losses will be around 119 million yuan for the first half of 2025, which is an increase of about 65.05 million yuan compared to the same period last year, reflecting a year-on-year increase of approximately 120% [1]